tradingkey.logo

Rigel Announces First Patient Enrolled In Dose Expansion Phase Of 1B Study Of R289 In Patients With Lower-Risk MDS

ReutersOct 8, 2025 12:26 PM

- Rigel Pharmaceuticals Inc RIGL.O:

  • RIGEL ANNOUNCES FIRST PATIENT ENROLLED IN THE DOSE EXPANSION PHASE OF ITS PHASE 1B STUDY OF R289 IN PATIENTS WITH LOWER-RISK MDS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI